All of the following are FDA-approved indications for lansoprazole, EXCEPT?

A. Erosive esophagitis is a labeled indication for lansoprazole to facilitate the healing of esophageal mucosal lesions. It functions as a proton pump inhibitor by irreversibly binding to the hydrogen-potassium ATPase enzyme. This suppresses gastric acid secretion effectively. B. Irritable bowel syndrome is a functional gastrointestinal disorder and not an FDA-approved indication for lansoprazole. This condition involves visceral hypersensitivity and altered motility rather than primary acid-related mucosal damage. Lansoprazole lacks the clinical evidence for this specific diagnosis. C. Gastroesophageal reflux disease is a primary indication where lansoprazole provides symptomatic relief by reducing the acidity of gastric contents. It targets the parietal cells to inhibit the final step of acid production. This reduces the corrosive impact on the esophagus. D. Gastric ulcer treatment is an approved use for lansoprazole to promote the healing of active benign gastric ulcers. It creates an alkaline environment conducive to mucosal repair by inhibiting the proton pump. It is also used for NSAID-associated gastric ulcers.